Increase of adenosine doses in fractional flow reserve

Assessment of increasing intravenous adenosine dose in fractional flow reserve: a non-randomized trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN14618196

Enrollment

Registered

2016-12-15

Start date

2013-01-10

Completion date

Unknown

Last updated

2020-12-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary artery disease Circulatory System Atherosclerotic heart disease

Interventions

Following coronary angiography and intracoronary administration of 200µg Nitroglycerin, a 0.014-inch pressure guide wire (Primewire Prestige®/Verrata® Pressure Guide Wire, Volcano Corporation, San Die

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Age =18 years 2. Borderline-significant coronary stenosis (indication for FFR according to ESC Guidelines) 3. Signed informed consent prior to enrollment

Exclusion criteria

Exclusion criteria: 1. Allergy to adenosine or contrast media 2. Baseline mean arterial pressure <60 mmHg 3. Baseline heart rate <50 bpm 4. Pharmacologically treated asthma 5. Chronic obstructive pulmonary disease equivalent to GOLD classification III and IV 6. Confusion or inability to comprehend the study information

Design outcomes

Primary

Measure	Time frame
Fractional Flow Reserve values, measured as described above after each dose	—

Secondary

Measure	Time frame
Discomfort, measured using the Visual Analogue Scale straight after FFR	—

Countries

Sweden

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 27, 2026